Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Venkata Mahidhar Yenugonda"'
Publikováno v:
BioTechniques. 68:180-184
CRISPR–Cas9 has proven to be a versatile tool for the discovery of essential genetic elements involved in various disease states. CRISPR-assisted dense mutagenesis focused on therapeutically challenging protein complexes allows us to systematically
Autor:
Varsha Harish, Sophie Coste, Stanley T. Fricke, Gary M. Kupfer, Muhammad S. Noon, Olga Rodriguez, Erika Parasido, Chris Albanese, Venkata Mahidhar Yenugonda, Aisha Naeem, Emanuel F. Petricoin, Lawrence F. Kromer, Maria Avantaggiati, Mariaelena Pierobon, Chukuemeka Ihemelandu, Muhammad Umer Choudhry
Publikováno v:
Mol Cancer Res
In medulloblastoma, p53 expression has been associated with chemoresistance and radiation resistance and with poor long-term outcomes in the p53-mutated sonic hedgehog, MYC-p53, and p53-positive medulloblastoma subgroups. We previously established a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c1f8552215a5f76e6c5eb40858aa290
https://europepmc.org/articles/PMC8738155/
https://europepmc.org/articles/PMC8738155/
Autor:
Achal S. Achrol, Anubhab Mukherjee, Santosh Kesari, Ariana K Waters, Venkata Mahidhar Yenugonda, Pranav Kalyan
Publikováno v:
International Journal of Nanomedicine. 14:1937-1952
Lipid-polymer hybrid nanoparticles (LPHNPs) are next-generation core-shell nanostructures, conceptually derived from both liposome and polymeric nanoparticles (NPs), where a polymer core remains enveloped by a lipid layer. Although they have garnered
Autor:
Tiffany Juarez, Venkata Mahidhar Yenugonda, Santosh Kesari, Mark C. Glassy, Elmar Nurmemmedov, Ivan Babic, Sandeep C. Pingle, Natsuko Nomura
Publikováno v:
Human Antibodies. 26:95-101
Immunotherapy is now at the forefront of cancer therapeutic development. Gliomas are a particularly aggressive form of brain cancer for which immunotherapy may hold promise. Pritumumab (also known in the literature as CLNH11, CLN-IgG, and ACA-11) was
Autor:
Ariana K Waters, Sandeep Burma, Annamarie Allnutt, Natsuko Nomura, Yueqin Quan, Elmar Nurmemmedov, Nozomi Tomimatsu, Ivan Babic, Venkata Mahidhar Yenugonda, Santosh Kesari
Publikováno v:
Neuro Oncol
Glioblastoma (GBM) is considered one of the most lethal forms of human cancers, and despite considerable advances in multimodality treatments, it remains an incurable disease with an overall survival of 14 to 16 months after diagnosis. Even in the er
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a91db327be778a2e59b248f76664b38
https://europepmc.org/articles/PMC7650350/
https://europepmc.org/articles/PMC7650350/
Autor:
Nam-Gu Her, Pengfei Jiang, Santosh Kesari, Elmar Nurmemmedov, Venkata Mahidhar Yenugonda, Rajesh Mukthavaram, Natsuko Nomura, Jatin Roper, Ivan Babic, Anton Cheltsov
Publikováno v:
Scientific Reports
Scientific Reports, Vol 10, Iss 1, Pp 1-11 (2020)
Scientific Reports, Vol 10, Iss 1, Pp 1-11 (2020)
Abnormal regulation of β-catenin initiates an oncogenic program that serves as a main driver of many cancers. Albeit challenging, β-catenin is an attractive drug target due to its role in maintenance of cancer stem cells and potential to eliminate
Publikováno v:
ACS chemical neuroscience. 11(9)
Cyclin-dependent kinase 5 (Cdk5) is a proline-directed serine (ser)/threonine (Thr) kinase that has been demonstrated to be one of the most functionally diverse kinases within neurons. Cdk5 is regulated via binding with its neuron-specific regulatory
Publikováno v:
Future Medicinal Chemistry. 10:1399-1403
Autor:
Igor F. Tsigelny, Venkata Mahidhar Yenugonda, Valentina Fogal, Natsuko Nomura, Elmar Nurmemmedov, Ivan Babic, Santosh Kesari, Valentina L. Kouznetsova
Publikováno v:
Journal of Translational Medicine, Vol 15, Iss 1, Pp 1-12 (2017)
Journal of Translational Medicine
Journal of Translational Medicine
Background The mitochondrial protein p32 is a validated therapeutic target of cancer overexpressed in glioma. Therapeutic targeting of p32 with monoclonal antibody or p32-binding LyP-1 tumor-homing peptide can limit tumor growth. However, these agent
Publikováno v:
Cancer journal (Sudbury, Mass.). 25(2)